Save the date! RheumNow Live is back on 3/18-3/19 in Dallas, Texas. Register now! https://t.co/tgce0Mydeh #RNL23 #ACR22 https://t.co/XI6hcxuNEn

• https://bit.ly/3G8Nj1J

Do you know the 3 types of Y. Pestis plague? @AdamJBrownMD reviews the Bubonic, Pneumonic, and Septicemia plagues at #ACR22 @RheumNow. Most recently, there was an outbreak of Pneumonic plague in Madagascar in the 2010s!

MEFV mutation protected against the plague. Protected against deactivation of inflammasome by yersinia pestis. @RheumNow #ACR22 #rheuminations https://t.co/OqBay6Svdb

GM-CSF/mavrilimumab in GCA masterclass from Maria Cid this morning. Sadly, as John Stone & Sharon Chung ask and Maria Cid reflects on, we're not sure what happens next, despite the promising phase 2 & elegant MOA. No current plans for a mavrilimumab GCA phase 3 #ACR22 @RheumNow https://t.co/c5PSqnFnC2

Ab0574 #ACR22: Osteoporosis in Men - Under-recognized? Under-Screened? Under-Diagnosed! @AMollaeianMD: Retrosp study >65 yo <1% M have DEXA compared to 7-10% in F in 2010, 2018, and 2021 Hip fx 4.1% F, 3% M DEXA declined in M between 2010-2018, no change in 2021 🦴🦴🩻 @RheumNow https://t.co/LbmxLnIX1Q

How to prescribe methotrexate in a post-Roe era: Abstract #L09 💊 6% of > 1,700 patients reported access issues to MTX -63% had a delay in filling script 🤰Excessive questions about possibility of pregnancy 🧑‍⚕️Pharmacy refused to fill #ACR22 #ACRbest @RheumNow

#ACR22 Abstr#0799 Is Evusheld effective in patients on B-cell depleting therapies? Early data (Jan-May 22) from @CCalabreseDO @LCalabreseDO are encouraging: 13/417 (3%) breakthrough infection in fully vac pts, 1 hospitalised. More data needed for Omicron subvariants @RheumNow https://t.co/g4Y1IMO67X

RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its Faculty

#ACR22 Abstr#0783. Rituximab impacts on humoral immunity. Our study on 400 RMD pts showed: Breakthrough infection 30% mostly mild; Severe 4%; 1 death Poor outcomes predicted by comorbidities & low IgG Risk reduced by 50% with each vac dose OK for RTX if vaccinated @RheumNow https://t.co/xyJsukm1Rh

☝️Remember: Not all skin thickening is SSc! 🔸Lipodermatosclerosis is a differential. Has an inverted champagne bottle appearance - caused by venous stasis and venous HTN #ACR22 @RheumNow #Scleroderma #RheumTwitter https://t.co/joWWn6BnVC

Song et al. Korean study shows better persistence of tocilizumab than TNFi as first-line biologic in RA. No difference in incidence of TB. @RheumNow #ACR22 Abstr#0887 https://t.co/EuQkfDZd77 https://t.co/VxJmKEzAVY

• Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necr…

Lanz et al. Inverse relationship between number of ACPAs and subclinical ILD. Effect appears confined to African American and Hispanic participants. Not sure what to make of this at all. @RheumNow #ACR22 Abstr#1203 https://t.co/Ok3PCLFyxe https://t.co/UHlI6HOUmc

• The Association Between Anti-Citrullinated Peptide Antibodies and Subclinical I…

Deodhar et al. Bimekizumab (IL-17A/Fi) in nr-axSpA. Efficacy shown across all outcomes. Confirms bimekizumab works across spectrum of axSpA (not surprisingly). @RheumNow #ACR22 Abstr#0544 https://t.co/XVGBgBQpTH https://t.co/39zW5Ex9xh

• Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients wi…

Hanlon @MeganHanlon4 @dougveale et al. Loss of macrophage homeostasis occurs in pre-RA, and appears to be an early factor in RA development @RheumNow #ACR22 Abstr#0554 https://t.co/UL1jVGVlrA https://t.co/i1WWQlHs2m

• Loss of Synovial Tissue Macrophage Homeostasis Precedes Rheumatoid Arthritis Cl…

Proft @ProftDr et al. NSAIDs+golimumab no better than golimumab monotherapy in reducing spinal progression in AS. But... for high risk patients there may be some benefit - see figure. @RheumNow #ACR22 Abstr#0546 https://t.co/xo9Uy6aX71 https://t.co/vZgaoeEQn4

• COmparison of the Effect of Treatment with NSAIDs Added to Anti-TNF Therapy ver…